Hyperion Defi, Inc. · NASDAQ:HYPD
Hyperion Defi — Eyenovia — Shareholder Meeting (June 2023)
11 slides from Hyperion Defi's shareholder meeting presentation, Jun 27, 2023
Slide 1: 2023 Annual Meeting
2023 Annual Meeting
Slide 2: Forward-looking Statements
1 Forward-looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, s
Slide 3: An Ophthalmic Technology Company With a Common Platform
2 An Ophthalmic Technology Company With a Common Platform The First FDA Approval for Optejet® Technology Metered ~8μL spray dosing of topical medication Horizontal delivery at the touch of a button
Slide 4: MydCombi: The First and Only Ophthalmic Spray for Mydriasis
3 MydCombi™ The First and Only Ophthalmic Spray for Mydriasis 1 Indication: MYDCOMBI (tropicamide 1% and phenylephrine HCl 2.5%) ophthalmic spray is indicated to induce mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired. IMPORTANT SAFETY INFORMAT
Slide 5: MydCombi Launch Timeline
4 Eyenovia Commercial Manufacturing Online MAY 2023 2024 JUL SEP NOV MydCombi Launch Timeline State Pharmacy Licenses Beta Launch Expanded Launch Required for Interstate Commerce Training and ordering system implementation
Slide 6: Eyenovia Has Met its Stated Corporate Objectives In The Past 12 Months
5 Eyenovia Has Met its Stated Corporate Objectives In The Past 12 Months Validation of Optejet technology with FDA approval of MydCombi Execution of our R&D/MFG strategic plan Preparations for Apersure™ (Microline) NDA in the consumer-friendly Gen-2 device
Slide 7: Optejet Gen-2 Is the Commercial Device for Apersure
6 • Improved ability to manufacture • Sleek ergonomic design • On board data collection and reporting integrates with AI systems Optejet Gen-2 Optejet Gen-2 is the Commercial Device for Apersure™ • 4 out of 5 patients preferred the Optejet over an eyedropper when considering presbyopia treatment1 •
Slide 8: Corporate Strategy is to Maximize the Value of Our Current and Potential Future Assets
7 Corporate Strategy is to Maximize the Value of Our Current and Potential Future Assets Opportunities Dry Eye Glaucoma Out-licensing in high-value therapeutic categories In-house product development: MydCombi Apersure Future/partnered product development MicroPine (Childhood Progressive Myopia)
Slide 9: Glaucoma and Dry Eye Represent 80% of the Value in Topical Ophthalmic Therapies
8 GLAUCOMA • Addresses need for an easier to administer product with potentially fewer side effects and added benefits such as dosing reminders • Digital technology may provide doctors and managed care organizations with an unbiased measure of patient adherence and compliance, enabling data-based de
Slide 10: Strategic Commercialization Timeline 2024-2028
9 Strategic Commercialization Timeline 2024-2028 MydCombi™ 2024 2028 Apersure™ Target: Dry Eye Target: Glaucoma 2025 2026 2027 Target: Licensed in New Molecular Entity Potential Partner Portfolio
Slide 11: Upcoming Potential Milestones
10 Upcoming Potential Milestones First Commercial Sale of MydCombi™ Potential Licensing and/or Partnership Agreements Planned NDA Filing for Apersure Production of Pre-NDA Batches for Apersure™ (Microline) 3Q 2023 4Q 2024